Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Januar 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Plimsoller
    wrote on sidst redigeret af
    #1082

    A nice surprise for them that the milestone was reached last year instead of last year. It however also proves that it is not important in the long run, hence they maintain their target price. I wonder if other analytics would have shared that line of thought in case the milestone unexpected was not reached.

    1 Reply Last reply
    0
    • P Offline
      P Offline
      Plimsoller
      wrote on sidst redigeret af
      #1083

      Thanks E L

      1 Reply Last reply
      0
      • P Offline
        P Offline
        Plimsoller
        wrote on sidst redigeret af
        #1084

        *instead of this year

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #1085

          @Plimsoller let's just say that i am glad we did not have to test that lol

          1 Reply Last reply
          0
          • P Offline
            P Offline
            Plimsoller
            wrote on sidst redigeret af
            #1086

            Agree 🙂

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #1087

              Pensionisten: Debatten i går aftes drejede sig ikke om fremtiden slet og ret. Den drejede sig om det fremtidige salg af Darzalex. Her har sc stor betydning. Hvis sc ikke kommer på markedet i større omfang i 2020, vil det få stor betydning for salget i 2020.

              1 Reply Last reply
              0
              • H Offline
                H Offline
                Hen
                wrote on sidst redigeret af
                #1088

                @StockBull Guiding for 2020 kommer vel i forbindelse med årsregnskabet
                d. 19 februar?

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #1089

                  En fidus til Genmab: Find ud af hvilke receptorer, der sidder på Corona-virus. Lav et antistof derimod - gerne bispecifikt. Det vil der være fremtid i. Fidusen hermed givet videre. 😉

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #1090

                    Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab https://clincancerres.aacrjournals.org/content/early/2020/01/22/1078-0432.CCR-19-2299 and in full pdf https://sci-hub.tw/https://clincancerres.aacrjournals.org/content/early/2020/01/22/1078-0432.CCR-19-2299

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1091

                      https://sci-hub.tw/https://clincancerres.aacrjournals.org/content/early/2020/01/22/1078-0432.CCR-19-2299

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #1092

                        Similar to our observations with JNJ-7957, the
                        activity of blinatumomab was significantly enhanced by co-incubation with daratumumab - ; prior or
                        concomitant daratumumab treatment may also be beneficial for other T-cell redirecting
                        therapies

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #1093

                          can you read this article in Denmark (it is blocked in NL) https://www.thetelegraph.com/business/article/J-J-looks-to-fend-off-challenges-to-key-drugs-14995067.php

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            Plimsoller
                            wrote on sidst redigeret af
                            #1094

                            No. Maybe one of the guys with VPN?

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #1095

                              451 Unavailable For Legal Reasons

                              1 Reply Last reply
                              0
                              • M Offline
                                M Offline
                                Mcjean
                                wrote on sidst redigeret af
                                #1096

                                VPN can handle it what do you want to know?

                                1 Reply Last reply
                                0
                                • M Offline
                                  M Offline
                                  Mcjean
                                  wrote on sidst redigeret af
                                  #1097

                                  Johnson & Johnson posted weaker-than-expected sales in the final quarter of 2019, raising the stakes for the health-care conglomerate as it banks on new cancer and immunology drugs to replace a group of aging blockbusters.

                                  Some of the company's most lucrative medicines are facing competition from generics and biosimilars. Arthritis drug Remicade's sales fell more than 16% from a year earlier in the quarter, while Zytiga, an older treatment for prostate cancer, saw a nearly 14% decline.

                                  1 Reply Last reply
                                  0
                                  • M Offline
                                    M Offline
                                    Mcjean
                                    wrote on sidst redigeret af
                                    #1098

                                    At the same time, J&J's storied consumer businesses are also being pressed by upstarts. Sales of its baby-care products declined more than 26% in the U.S. as consumers increasingly look for alternatives to the company's shampoos, lotions and other one-time medicine-cabinet staples.

                                    1 Reply Last reply
                                    0
                                    • M Offline
                                      M Offline
                                      Mcjean
                                      wrote on sidst redigeret af
                                      #1099

                                      As the company adapts to those changes, it also is confronting increasing political blowback over high drug prices, trade turbulence and a series of lawsuits tied to a range of its products, from opioids to baby powder.
                                      J&J looks to fend off challenges to key drugs, consumer products

                                      Riley Griffin, Bloomberg Published 10:20 am CST, Wednesday, January 22, 2020

                                      Johnson & Johnson Listerine brand mouthwash on Jan. 14, 2020. Photo: Bloomberg Photo By Tiffany Hagler-Geard. / © 2020 Bloomberg F

                                      1 Reply Last reply
                                      0
                                      • M Offline
                                        M Offline
                                        Mcjean
                                        wrote on sidst redigeret af
                                        #1100

                                        Overall, the New Brunswick, New Jersey-based company reported fourth-quarter revenue of $20.75 billion, just short of the $20.87 billion analysts had expected.

                                        J&J shares declined 0.9% to $147.93 at 10:47 a.m. in New York on Wednesday. They had advanced 16% in the past 12 months through Tuesday's close.

                                        In the year ahead, J&J is likely to draw much of its growth from sales of cancer and immunology drugs. For 2020, adjusted earnings per share are expected to be $8.95 to $9.10. Heading into

                                        1 Reply Last reply
                                        0
                                        • K Offline
                                          K Offline
                                          KWC
                                          wrote on sidst redigeret af
                                          #1101

                                          Horizon Therapeutics Secures U.S. FDA Approval for Teprotumumab, for the Treatment of Thyroid Eye Disease (TED)
                                          Media Release

                                          Copenhagen, Denmark, January 23, 2020

                                          ·Third Genmab-created product approved by the U.S. FDA

                                          Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted approval to Horizon Therapeutics (Nasdaq: HZNP) for the use of teprotumumab, under the trade name TEPEZZA™ (teprotumumab-trbw), for the treatment of Thyroid Eye D

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger